aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Nausea and Vomiting (CINV)
Conditions
Chemotherapy-induced Nausea and Vomiting (CINV)
Trial Timeline
Aug 25, 2009 โ May 5, 2010
NCT ID
NCT00952341About aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone is a phase 3 stage product being developed by Merck for Chemotherapy-induced Nausea and Vomiting (CINV). The current trial status is completed. This product is registered under clinical trial identifier NCT00952341. Target conditions include Chemotherapy-induced Nausea and Vomiting (CINV).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00952341 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy-induced Nausea and Vomiting (CINV)